AIM ImmunoTech Inc.

2.38+0.1000+4.39%Vol 1.14M1Y Perf -8.11%
Jun 14th, 2021 16:00 DELAYED
BID2.38 ASK2.40
Open2.31 Previous Close2.28
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap113.84M 
Earnings Rating
Price Range Ratio 52W %
28.89 
Earnings Date
19th May 2021

Today's Price Range

2.282.40

52W Range

1.604.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
9.68%
1 Month
18.41%
3 Months
3.93%
6 Months
35.23%
1 Year
-8.11%
3 Years
-82.02%
5 Years
-99.66%
10 Years
-99.90%

TickerPriceChg.Chg.%
AIM2.380.10004.39
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Financial StrengthValueIndustryS&P 500US Markets
52.60
52.80
0.03
0.03
-34.40
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-474.70
-9 432.20
-8 905.50
-5 653.90
-
RevenueValueIndustryS&P 500US Markets
146.00K
0.00
-28.34
3.04
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.08-
Q04 2020--0.09-
Q03 2020--0.08-
Q02 2020--0.11-
Q01 2020--0.22-
Q03 2019--1.13-
Q02 2019--1.07-
Q01 2019--0.07-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.14M
Shares Outstanding47.83M
Trades Count4.05K
Dollar Volume4.45M
Avg. Volume1.91M
Avg. Weekly Volume628.83K
Avg. Monthly Volume506.30K
Avg. Quarterly Volume637.47K

AIM ImmunoTech Inc. (AMEX: AIM) stock closed at 2.38 per share at the end of the most recent trading day (a 4.39% change compared to the prior day closing price) with a volume of 1.21M shares and market capitalization of 113.84M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. AIM ImmunoTech Inc. CEO is Thomas K. Equels.

The one-year performance of AIM ImmunoTech Inc. stock is -8.11%, while year-to-date (YTD) performance is 32.96%. AIM stock has a five-year performance of -99.66%. Its 52-week range is between 1.6 and 4.3, which gives AIM stock a 52-week price range ratio of 28.89%

AIM ImmunoTech Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 10.31, a price-to-sale (PS) ratio of 647.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.78%, a ROC of -24.76% and a ROE of -26.54%. The company’s profit margin is -%, its EBITDA margin is -8 905.50%, and its revenue ttm is $146.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from AIM ImmunoTech Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AIM ImmunoTech Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for AIM ImmunoTech Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AIM ImmunoTech Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AIM ImmunoTech Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AIM ImmunoTech Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 41.44, ATR14 : 0.09, CCI20 : 216.52, Chaikin Money Flow : 0.13, MACD : 0.05, Money Flow Index : 73.74, ROC : 12.80, RSI : 71.62, STOCH (14,3) : 94.59, STOCH RSI : 1.00, UO : 61.00, Williams %R : -5.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AIM ImmunoTech Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

CEO: Thomas K. Equels

Telephone: +1 352 448-7797

Address: 2117 SW Highway 484, Ocala 34473, FL, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

75%25%

Bearish Bullish

80%20%

News

Stocktwits